BIO
Bio-Rad Laboratories, Inc. NYSE Listed Feb 27, 1980$282.44
-0.78%
vs $284.67
Mkt Cap $7.7B
52w Low $232.00
46.8% of range
52w High $339.75
50d MA $283.39
200d MA $293.72
P/E (TTM)
10.1x
EV/EBITDA
15.8x
P/B
1.0x
Debt/Equity
0.2x
ROE
10.2%
P/FCF
20.6x
RSI (14)
24.70
ATR (14)
$8.38
Beta
1.16
50d MA
$283.39
200d MA
$293.72
Avg Volume
410.3K
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
1000 Alfred Nobel Drive · Hercules, CA 94547 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 1.97 | 1.89 | -4.1% | 280.12 | -6.7% | -8.4% | +0.5% | -0.3% | +0.7% | -0.7% | — |
| Feb 12, 2026 | AMC | 2.57 | 2.51 | -2.3% | 292.42 | -14.2% | -12.3% | +3.3% | +2.2% | +0.5% | -0.2% | — |
| Oct 29, 2025 | AMC | 2.30 | 2.26 | -1.7% | 319.47 | -1.1% | -4.7% | +4.9% | -2.5% | -0.2% | -0.3% | — |
| Jul 31, 2025 | AMC | 1.93 | 2.61 | +35.2% | 241.95 | +12.0% | +17.6% | -2.7% | -1.7% | -2.9% | +0.4% | — |
| May 1, 2025 | AMC | 1.73 | 2.54 | +46.8% | 240.43 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% | — |
| Feb 13, 2025 | AMC | 2.86 | 2.90 | +1.4% | 306.36 | -1.4% | -9.5% | +2.2% | +0.2% | +0.7% | -1.9% | — |
| Oct 30, 2024 | AMC | 1.28 | 2.01 | +57.0% | 330.58 | +5.4% | +8.4% | +2.9% | +0.1% | +1.5% | -0.4% | — |
| Aug 1, 2024 | AMC | 2.12 | 3.11 | +46.7% | 341.25 | -1.4% | -1.6% | -2.2% | -0.5% | -2.5% | +3.0% | — |
| May 7, 2024 | AMC | 2.15 | 2.29 | +6.5% | 279.91 | -2.6% | -4.2% | +3.4% | +1.7% | +1.2% | +3.0% | — |
| Feb 15, 2024 | AMC | 2.93 | 3.10 | +5.8% | 328.73 | +6.5% | +3.6% | +1.0% | -1.5% | -0.1% | -0.1% | — |
| Oct 26, 2023 | AMC | 2.87 | 2.33 | -18.8% | 291.53 | -5.9% | -7.2% | -0.5% | +2.2% | +0.8% | +1.3% | — |
| Aug 3, 2023 | AMC | 2.55 | 3.00 | +17.6% | 401.80 | +1.7% | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15 | RBC Capital Mkts | Reiterates | Outperform | $320 | $246.27 | $248.46 | +0.9% | +0.5% | +13.9% | -0.3% | +2.4% | -0.4% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $280.12 | $261.47 | -6.7% | -8.4% | +0.5% | -0.3% | +0.7% | -0.7% |
| Apr 7 | Citigroup | Downgrade | Buy → Neutral | — | $278.85 | $272.21 | -2.4% | -0.3% | +1.1% | -1.3% | +0.6% | +3.2% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $319.47 | $316.00 | -1.1% | -4.7% | +4.9% | -2.5% | -0.2% | -0.3% |
| Oct 30 | Citigroup | Maintains | Buy → Buy | — | $319.47 | $316.00 | -1.1% | -4.7% | +4.9% | -2.5% | -0.2% | -0.3% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $241.95 | $270.93 | +12.0% | +17.6% | -2.7% | -1.7% | -2.9% | +0.4% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $241.95 | $270.93 | +12.0% | +17.6% | -2.7% | -1.7% | -2.9% | +0.4% |
| Jun 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $219.42 | $222.81 | +1.5% | +2.8% | +2.2% | -0.1% | +1.0% | -2.4% |
| May 2 | UBS | Maintains | Buy → Buy | — | $240.43 | $250.00 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% |
| May 2 | RBC Capital | Maintains | Outperform → Outperform | — | $240.43 | $250.00 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% |
| May 2 | Citigroup | Maintains | Buy → Buy | — | $240.43 | $250.00 | +4.0% | -1.7% | +1.6% | -3.6% | +0.4% | +3.6% |
| Apr 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $245.21 | $243.06 | -0.9% | -2.9% | -0.5% | +3.4% | +1.6% | +0.4% |
| Feb 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $314.73 | $310.70 | -1.3% | -0.8% | -1.9% | -9.5% | +2.2% | +0.2% |
| Jan 14 | RBC Capital | Maintains | Outperform → Outperform | — | $351.70 | $351.70 | +0.0% | -2.7% | -0.1% | +0.8% | -0.6% | +3.3% |
| Dec 9 | RBC Capital | Maintains | Outperform → Outperform | — | $325.50 | $324.83 | -0.2% | +6.2% | -1.7% | +0.5% | -0.4% | -1.1% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $330.58 | $348.47 | +5.4% | +8.4% | +2.9% | +0.1% | +1.5% | -0.4% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $330.58 | $348.47 | +5.4% | +8.4% | +2.9% | +0.1% | +1.5% | -0.4% |
| Oct 1 | Citigroup | Upgrade | Neutral → Buy | — | $334.58 | $338.55 | +1.2% | +0.9% | +1.5% | -1.6% | +2.0% | -0.8% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $325.62 | $325.59 | -0.0% | -0.0% | +0.2% | -2.3% | -0.8% | -2.0% |
| Aug 2 | Citigroup | Maintains | Neutral → Neutral | — | $341.25 | $336.54 | -1.4% | -1.6% | -2.2% | -0.5% | -2.5% | +3.0% |
| Aug 2 | RBC Capital | Maintains | Outperform → Outperform | — | $341.25 | $336.54 | -1.4% | -1.6% | -2.2% | -0.5% | -2.5% | +3.0% |
| May 8 | UBS | Maintains | Buy → Buy | — | $279.91 | $272.52 | -2.6% | -4.2% | +3.4% | +1.7% | +1.2% | +3.0% |
| Apr 3 | Citigroup | Downgrade | Buy → Neutral | — | $328.72 | $322.13 | -2.0% | -0.2% | -1.6% | +0.5% | +0.5% | +4.0% |
| Feb 16 | RBC Capital | Maintains | Outperform → Outperform | — | $328.73 | $350.00 | +6.5% | +3.6% | +1.0% | -1.5% | -0.1% | -0.1% |
| Feb 16 | UBS | Maintains | Buy → Buy | — | $328.73 | $350.00 | +6.5% | +3.6% | +1.0% | -1.5% | -0.1% | -0.1% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $400.00 | $398.54 | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% | -0.2% |
| Aug 4 | Credit Suisse | Maintains | Outperform → Outperform | — | $401.80 | $408.79 | +1.7% | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% |
| Aug 4 | RBC Capital | Maintains | Outperform → Outperform | — | $401.80 | $408.79 | +1.7% | -0.4% | +0.4% | +0.3% | -1.5% | +0.3% |
| May 8 | Citigroup | Maintains | Buy → Buy | — | $385.24 | $384.69 | -0.1% | -1.8% | -3.0% | -0.3% | -0.4% | +2.2% |
| May 8 | RBC Capital | Maintains | Outperform → Outperform | — | $385.24 | $384.69 | -0.1% | -1.8% | -3.0% | -0.3% | -0.4% | +2.2% |
| May 5 | Credit Suisse | Maintains | Outperform → Outperform | — | $462.61 | $400.00 | -13.5% | -16.7% | -1.8% | -3.0% | -0.3% | -0.4% |
| Feb 17 | Credit Suisse | Maintains | Outperform → Outperform | — | $455.91 | $455.00 | -0.2% | +6.0% | -3.1% | +1.7% | +2.3% | -1.4% |
| Feb 17 | RBC Capital | Maintains | Outperform → Outperform | — | $455.91 | $455.00 | -0.2% | +6.0% | -3.1% | +1.7% | +2.3% | -1.4% |
| Dec 7 | RBC Capital | Maintains | Outperform → Outperform | — | $399.59 | $401.97 | +0.6% | +1.1% | +4.0% | -1.0% | +0.5% | +4.0% |
| Oct 28 | Credit Suisse | Maintains | Outperform → Outperform | — | $385.02 | $365.70 | -5.0% | -8.0% | -0.7% | +1.9% | -0.7% | +2.6% |
| Aug 25 | Credit Suisse | Maintains | Outperform → Outperform | — | $499.09 | $505.55 | +1.3% | +3.1% | -3.8% | -1.4% | -1.0% | +0.3% |
| Jul 8 | Citigroup | Maintains | Buy → Buy | — | $512.54 | $506.13 | -1.3% | +0.9% | +0.9% | -4.1% | -0.2% | -2.2% |
| Jul 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $707.13 | $713.11 | +0.8% | +4.6% | -0.4% | +1.3% | +2.2% | +0.2% |
| Feb 12 | Citigroup | Maintains | Buy → Buy | — | $643.81 | $650.00 | +1.0% | +2.9% | -1.9% | +0.9% | -0.6% | -2.2% |
| Feb 5 | Jefferies | Maintains | Buy → Buy | — | $605.01 | $608.62 | +0.6% | +1.9% | +2.0% | +1.2% | -0.7% | +1.9% |
| Jul 31 | Citigroup | Maintains | Buy → Buy | — | $535.60 | $524.93 | -2.0% | -2.0% | +1.2% | -0.8% | +0.1% | -0.4% |
| May 21 | Wells Fargo | Maintains | Overweight → Overweight | — | $472.94 | $474.90 | +0.4% | -1.3% | +1.2% | +1.8% | -2.2% | +1.4% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $449.99 | $464.46 | +3.2% | +2.3% | -0.9% | +3.1% | -1.9% | -1.4% |
| Apr 20 | Citigroup | Maintains | Buy → Buy | — | $427.21 | $426.12 | -0.3% | -0.5% | -1.7% | +0.9% | +0.4% | +2.3% |
| Mar 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $322.41 | $326.18 | +1.2% | +8.3% | +0.4% | -4.5% | +7.7% | +1.4% |
| Mar 26 | Barclays | Maintains | Overweight → Overweight | — | $333.00 | $337.37 | +1.3% | +2.5% | -5.5% | +8.3% | +0.4% | -4.5% |
| Mar 20 | Citigroup | Maintains | Buy → Buy | — | $346.80 | $347.35 | +0.2% | -5.1% | -0.8% | +5.2% | -3.0% | +2.5% |
| Feb 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $379.34 | $380.70 | +0.4% | +6.4% | +0.9% | +0.4% | +0.0% | -2.1% |
| Jan 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $380.54 | $384.25 | +1.0% | +0.3% | +1.8% | -1.3% | +0.2% | +0.0% |
| Jan 7 | Citigroup | Maintains | Buy → Buy | — | $372.03 | $374.94 | +0.8% | +2.3% | +0.3% | +1.8% | -1.3% | +0.2% |
No insider trades available.
8-K · 5.02
!!! Very High
Bio-Rad Laboratories, Inc.Class A -- 8-K 5.02: Executive Change
Bio-Rad's departure of a key executive creates leadership uncertainty that could impact operational continuity and investor confidence, warranting caution until a qualified successor is named.
Apr 24
8-K · 7.01
! Medium
Bio-Rad Laboratories, Inc.Class A -- 8-K 7.01: Regulation FD Disclosure
Bio-Rad Laboratories disclosed updated financial information regarding its Sartorius AG investment following Sartorius's 2025 earnings release, providing investors transparency on this significant equity holding's performance.
Feb 19
8-K · 7.01
! Medium
Bio-Rad Laboratories, Inc.Class A -- 8-K 7.01: Regulation FD Disclosure
Bio-Rad Laboratories disclosed supplemental earnings presentation materials under Regulation FD, providing investors with additional financial and operational details beyond standard earnings reports.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | First Eagle Investment Management, Llc | 5,205,544 | $1.5B | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 831,165 | $232M | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 829,186 | $231M | New | Mar 2026 |
| 4 | Ariel Investments, Llc | 785,961 | $219M | Added | Mar 2026 |
| 5 | Capital World Investors | 450,000 | $125M | New | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 444,957 | $124M | Reduced | Mar 2026 |
| 7 | First Pacific Advisors, Lp | 407,358 | $114M | Added | Mar 2026 |
| 8 | Morgan Stanley | 372,774 | $113M | Added | Dec 2025 |
| 9 | Capital Research Global Investors | 385,579 | $107M | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 354,365 | $99M | Added | Mar 2026 |
| 11 | Sei Investments Co | 287,912 | $80M | Reduced | Mar 2026 |
| 12 | Barclays Plc | 278,835 | $78M | Added | Mar 2026 |
| 13 | Parnassus Investments, Llc | 254,305 | $71M | Added | Mar 2026 |
| 14 | Deerfield Management Company, L.p. | 226,070 | $63M | — | Mar 2026 |
| 15 | Northern Trust Corp | 218,497 | $61M | Added | Mar 2026 |
| 16 | Nomura Holdings Inc | 217,342 | $61M | New | Mar 2026 |
| 17 | Thompson Siegel & Walmsley Llc | 176,465 | $49M | Reduced | Mar 2026 |
| 18 | Franklin Resources Inc | 170,354 | $47M | Added | Mar 2026 |
| 19 | Gotham Asset Management | 152,384 | $42M | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 148,669 | $41M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$7.71B
Enterprise Value
$7.50B
P/E (TTM)
10.13x
Forward P/E
27.44x
PEG Ratio
-0.08x
P/B
1.03x
P/S
2.98x
P/FCF
20.57x
EV/EBITDA
15.76x
Shares Out
27.3M
Financials (TTM)
Revenue
$2.58B
Net Income
$759.9M
EBITDA
$475.9M
Free Cash Flow
$374.6M
Op Cash Flow
$532.2M
EPS Basic
$27.87
EPS Diluted
$27.87
EPS Forward
$10.29
Gross Margin
52.0%
Op Margin
10.5%
Net Margin
29.4%
Balance Sheet
Total Assets
$10.58B
Total Liab.
$3.12B
Total Equity
$7.45B
Cash
$1.54B
LT Debt
$1.34B
Book Value/Sh
$273.40
Debt/Equity
0.21x
Current Ratio
5.62
Quick Ratio
4.19
Returns & Growth
ROE
10.2%
ROA
7.2%
ROIC
2.0%
Rev Growth YoY
+0.7%
EPS Growth YoY
+142.6%
Price Returns
2W
+26.9%
1M
+11.6%
3M
+12.2%
6M
-3.8%
12M
+37.7%
Technicals
52W High
$339.75
52W Low
$232.00
50d MA
$283.39
200d MA
$293.72
RSI (14)
24.70
ATR (14)
$8.38
Beta
1.16
Avg Volume
410K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$327.50
High
$335.00
Low
$320.00
Median
$327.50
Data updated apr 24, 2026 9:39pm
· Source: financialmodelingprep.com